CHChunhai Hao

Chunhai Hao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chunhai Hao has a total of 52 co-authors. Here are the top co-authors by number of shared publications:

  • Anita C. Bellail

    The Department of Pathology & Laboratory Medicine, Emory University, Atlanta, Georgia, United States of America

    9 shared publications
  • Feng Wei

    Department of Hepatopancreatobiliary Surgery, First Hospital of Jilin University, Changchun, Jilin, China

    4 shared publications
  • Jeffrey J. Olson

    Department of Pathology & Laboratory Medicine, Neurosurgery, Hematology & Medical Oncology, Winship Cancer Institute, Emory University School Medicine, Atlanta, GA 30322, USA

    4 shared publications
  • Jin Hyang Song

    Center for Inflammation Science and Systems Medicine, University of Florida Scripps Research Institute, Jupiter, FL 33458, USA

    4 shared publications
  • Anita C. Bellail

    Department of Pathology & Laboratory Medicine, Emory University, Atlanta, GA 30322, USA

    2 shared publications
  • Guangyi Wang

    Department of Hepatopancreatobiliary Surgery, First Hospital of Jilin University, Changchun, Jilin, China

    2 shared publications

Latest Publications

  • Open Access

    The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin

    by Quan Wang, Feng Wei, Guoyue Lv, Chunsheng Li, Tongjun Liu, Costas G Hadjipanayis, Guikai Zhang, Chunhai Hao, Anita C Bellail

    There is growing evidence indicating the insulin-like growth factor 1 receptor (IGF-1R) plays a critical role in the progression of human colorectal carcinomas. IGF-1R is an attractive drug target for the treatment of colon cancer. Picropodophyllin (PPP), of the cyclolignan family, has recently been identified as an IGF-1R inhibitor. The aim of this study is to determine the therapeutic response and mechanism after colorectal carcinoma treatment with PPP.


  • Retracted
    Open Access

    Combination of mTOR and EGFR Kinase Inhibitors Blocks mTORC1 and mTORC2 Kinase Activity and Suppresses the Progression of Colorectal Carcinoma

    by Quan Wang, Feng Wei, Chunsheng Li, Guoyue Lv, Guangyi Wang, Tongjun Liu, Anita C. Bellail, Chunhai Hao

    Mammalian target of rapamycin complex 1 and 2 (mTORC1/2) are overactive in colorectal carcinomas; however, the first generation of mTOR inhibitors such as rapamycin have failed to show clinical benefits in treating colorectal carcinoma in part due to their effects only on mTORC1. The second generation of mTOR inhibitors such as PP242 targets mTOR kinase; thus, they are capable of inhibiting both mTORC1 and mTORC2. To examine the therapeutic potential of the mTOR kinase inhibitors, we treated a panel of colorectal carcinoma cell lines with PP242. Western blotting showed that the PP242 inhibition of mTORC2-mediated AKT phosphorylation at Ser 473 (AKTS473) was transient only in the first few hours of the PP242 treatment. Receptor tyrosine kinase arrays further revealed that PP242 treatment increased the phosphorylated epidermal growth factor receptor (EGFR) at Tyr 1068 (EGFRT1068). The parallel increase of AKTS473 and EGFRT1068 in the cells following PP242 treatment raised the possibility that EGFR phosphorylation might contribute to the PP242 incomplete inhibition of mTORC2. To test this notion, we showed that the combination of PP242 with erlotinib, an EGFR small molecule inhibitor, blocked both mTORC1 and mTORC2 kinase activity. In addition, we showed that the combination treatment inhibited colony formation, blocked cell growth and induced apoptotic cell death. A systemic administration of PP242 and erlotinib resulted in the progression suppression of colorectal carcinoma xenografts in mice. This study suggests that the combination of mTOR kinase and EGFR inhibitors may provide an effective treatment of colorectal carcinoma.


  • Open Access

    TRAIL apoptotic pathway-targeted therapies for NSCLC

    by Anita C. Bellail, Chunhai Hao


  • Open Access

    Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells

    by Chunhai Hao, Bo Li, Shuohui Gao, Feng Wei, Anita C. Bellail, Tongjun Liu

    Epidermal growth factor receptor (EGFR) is highly expressed in colorectal carcinomas and, as a result, it leads to the activation of downstream mammalian target of rapamycin (mTOR) kinase pathways for cancer growth and progression. Clinical and preclinical studies, however, have shown that inhibition of epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) alone is not sufficient to treat colorectal carcinomas. In search of effective combination therapies, we show here that simultaneous targeting of EGFR with its inhibitor, erlotinib and mTOR with its inhibitor, rapamycin inhibits the phosphorylation and activation of downstream phosphatidylinositol 3-kinase (PI3K), Akt, mTOR and extracellular-signal-regulated kinase 1/2 (Erk1/2) pathways, resulting in the inhibition of cell cycle progression and the growth of both KRAS wild-type and mutated colorectal carcinoma cells. This study has demonstrated the principle that the combination of erlotinib and rapamycin may provide an effective therapy for colorectal carcinomas.


  • K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas

    by Feng Wei, Yan Liu, Anita C. Bellail, Jeffrey J. Olson, Shi-Yong Sun, Guoyue Lu, Lijuan Ding, Changji Yuan, Guangyi Wang, Chunhai Hao


  • A20 Ubiquitin Ligase–Mediated Polyubiquitination of RIP1 Inhibits Caspase-8 Cleavage and TRAIL-Induced Apoptosis in Glioblastoma

    by Anita C. Bellail, Jeffrey J. Olson, Xiaolu Yang, Zhijian J. Chen, Chunhai Hao

    The TNF-related apoptosis-inducing ligand (TRAIL) apoptotic pathway has emerged as a therapeutic target for the treatment of cancer. However, clinical trials have proven that the vast majority of human cancers are resistant to TRAIL apoptotic pathway-targeted therapies. We show that A20-mediated ubiquitination inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma through 2 signaling complexes. A20 is highly expressed in glioblastomas and, together with the death receptor 5 and receptor-interacting protein 1, forms a plasma membrane-bound preligand assembly complex under physiologic conditions. Treatment with TRAIL leads to the recruitment of caspase-8 to the plasma membrane-bound preligand assembly complex for the assembly of a death-inducing signaling complex. In the death-inducing signaling complex, the C-terminal zinc finger (Znf) domain of the A20 ubiquitin ligase mediates receptor-interacting protein 1 polyubiquitination through lysine-63-linked polyubiquitin chains, which bind to the caspase-8 protease domain and inhibit caspase-8 dimerization, cleavage, and the initiation of TRAIL-induced apoptosis in glioblastoma-derived cell lines and tumor-initiating cells. Significance: These results identify A20 E3 ligase as a therapeutic target whose inhibition can overcome TNF-related apoptosis-inducing ligand resistance in glioblastoma and thus have an impact on ongoing clinical trials of TNF-related apoptosis-inducing ligand-targeted combination cancer therapies. Cancer Discovery; 2(2); 140–55. © 2012 AACR. Read the Commentary on this article by Verbrugge and Johnstone, p. 112. This article is highlighted in the In This Issue feature, p. 95.


  • Heterogeneity of primary glioblastoma cells in the expression of caspase-8 and the response to TRAIL-induced apoptosis

    by Ling Qi, Anita C. Bellail, Michael R. Rossi, Zhaobin Zhang, Hui Pang, Stephen Hunter, Cynthia Cohen, Carlos S. Moreno, Jeffrey J. Olson, Shibo Li, et al.

    Recent studies suggest that cancer stem cells (CSCs) are responsible for cancer resistance to therapies. We therefore investigated how glioblastoma-derived CSCs respond to the treatment of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Neurospheres were generated from glioblastomas, characterized for CSC properties including self-renewal, cell differentiation and xenograft formation capacity, and analyzed for TRAIL-induced apoptosis, CASP8 genomic status, and caspase-8 protein expression. The neurosphere NSC326 was sensitive to TRAIL-induced apoptosis as evidenced by cell death and caspase-8, -3, and -7 enzymatic activities. In contrast, however, the neurosphere NSC189 was TRAIL-resistant. G-banding analysis identified five chromosomally distinguishable cell populations in the neurospheres. Fluorescence in situ hybridization revealed the variation of chromosome 2 copy number in these populations and the loss of CASP8 locus in 2q33-34 region in a small set of cell populations in the neurosphere. Immunohistochemistry of NSC189 cell blocks revealed the lack of caspase-8 protein in a subset of neurosphere cells. Western blotting and immunohistochemistry of human glioblastoma tumors demonstrated the expression of caspase-8 protein in the vast majority of the tumors as compared to normal human brain tissues that lack the caspase-8 expression. This study shows heterogeneity of glioblastomas and derived CSCs in the genomic status of CASP8, expression of caspase-8, and thus responsiveness to TRAIL-induced apoptosis. Clinic trials may consider genomic analysis of the cancer tissue to identify the genomic loss of CASP8 and use it as a genomic marker to predict the resistance of glioblastomas to TRAIL apoptosis pathway-targeted therapies.


  • Open Access

    DR5‐mediated DISC controls caspase‐8 cleavage and initiation of apoptosis in human glioblastomas

    by Anita C. Bellail, Margaret C. L. Tse, Jin H. Song, Surasak Phuphanich, Jeffrey J. Olson, Shi Yong Sun, Chunhai Hao

    To explore the molecular mechanisms by which glioblastomas are resistant to tumour necrosis factor‐related apoptosis‐inducing ligand (TRAIL), we examined TRAIL signalling pathways in the tumours. TRAIL has four membrane‐anchored receptors, death receptor 4/5 (DR4/5) and decoy receptor 1/2 (DcR1/2). Of these receptors, only DR5 was expressed consistently in glioblastoma cell lines and tumour tissues, ruling out the role of DcR1/2 in TRAIL resistance. Upon TRAIL binding, DR5 was homotrimerized and recruited Fas‐associated death domain (FADD) and caspase‐8 for the assembly of death‐inducing signalling complex (DISC) in the lipid rafts of the plasma membrane. In the DISC, caspase‐8 was cleaved and initiated apoptosis by cleaving downstream caspases in TRAIL‐sensitive glioblastoma cells. In TRAIL‐resistant cells, however, DR5‐mediated DISC was modified by receptor‐interacting protein (RIP), cellular FADD‐like interleukin‐1β‐converting enzyme inhibitory protein (c‐FLIP) and phosphoprotein enriched in diabetes or in astrocyte‐15 (PED/PEA‐15). This DISC modification occurred in the non‐raft fractions of the plasma membrane and resulted in the inhibition of caspase‐8 cleavage and activation of nuclear factor‐κB (NF‐κB). Treatment of resistant cells with parthenolide, an inhibitor of inhibitor of κB (I‐κB), eliminated TRAIL‐induced NF‐κB activity but not TRAIL resistance. In contrast, however, targeting of RIP, c‐FLIP or PED/PEA‐15 with small interfering RNA (siRNA) led to the redistribution of the DISC from non‐rafts to lipid rafts and eliminated the inhibition of caspase‐8 cleavage and thereby TRAIL resistance. Taken together, this study indicates that the DISC modification by RIP, c‐FLIP and PED/PEA‐15 is the most upstream event in TRAIL resistance in glioblastomas.